Table 4.
Probability of target T >4 × MIC attainment for various MICs
| Adequate PK N (%) | |||||
|---|---|---|---|---|---|
| MIC (μg/mL) | Target concentration (μg/mL) | meropenem (n = 16) | ceftazidime (n = 18) | cefepime (n = 19) | piperacillin-tazobactam (n = 27) |
| 32 | 128 | 0 | 0 | 0 | 1 (4) |
| 16 | 64 | 0 | 0 | 1 (5) | 12 (44) |
| 8 | 32 | 0 | 5 (28) | 3 (16) | 15 (56) |
| 4 | 16 | 3 (18) | 14 (78) | 7 (36) | 21 (78) |
| 2 | 8 | 12 (75) | 18 (100) | 15 (79) | 25 (93) |
| 1 | 4 | 15 (94) | 18 (100) | 17 (90) | 27 (100) |
| 0.5 | 2 | 16 (100) | 18 (100) | 19 (100) | 27 (100) |
Data are expressed as counts (percentage). In bold: MIC corresponding to European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints for Pseudomonas aeruginosa.
MIC, minimal inhibitory concentration; PK, pharmacok inetics.